Basket cover image
16 handpicked stocks

Ruthlessly Efficient

Explore a carefully curated collection of companies transforming how business gets done through automation, speed, and frictionless operations. These stocks, selected by our expert analysts, represent leaders in the relentless pursuit of operational excellence and cost reduction.

stock
stock
stock
stock
stock
stock
stock
stock
stock
stock

+6

Author avatar

Han Tan | Market Analyst

Updated 3 days ago | Published at जून 17

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

SYM

Symbotic Inc

SYM

Current price

$46.80

Develops AI-powered robotic systems that fully automate warehouse and supply chain operations for major retailers.

VYX

NCR Corp.

VYX

Current price

$12.45

Provides essential self-checkout kiosks and automated point-of-sale systems for the retail and restaurant industries.

CGNX

Cognex Corporation

CGNX

Current price

$43.40

Provides machine vision systems that are crucial for automating high-speed manufacturing and distribution tasks.

About This Group of Stocks

1

Our Expert Thinking

These companies are united by their focus on eliminating human friction from transactions and operations. As labor costs rise and efficiency becomes paramount, businesses that automate high-volume tasks and reduce operational complexity are positioned to thrive in the evolving economic landscape.

2

What You Need to Know

This collection spans multiple sectors but shares a common thread: replacing manual processes with automated, scalable systems. From robotic warehouses to self-checkout kiosks and payment processing platforms, these companies help businesses slash costs while handling massive transaction volumes.

3

Why These Stocks

We've selected market leaders in automation technology whose primary business is creating efficiency through technology. With persistent wage inflation and tight labor markets, these pure-play automation providers offer solutions that have become a competitive necessity, not just a nice-to-have option.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+17.15%

Group Performance Snapshot

17.15%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 17.15% over the next year.

14 of 15

Stocks Rated Buy by Analysts

14 of 15 assets in this group are rated Buy by professional analysts.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

🤖

Labor Woes Fuel Adoption

With persistent worker shortages and wage inflation, companies are rushing to automate. These stocks provide the solutions businesses need right now to maintain operations and protect margins.

📊

Scale Without Limits

Unlike human-powered businesses, these companies can scale operations rapidly without proportional cost increases. Their technology handles millions of transactions with minimal added expense.

💰

Margin Magic

These efficiency enablers help businesses dramatically reduce their operational costs. As adoption accelerates, these providers stand to capture increasing revenue streams from companies desperate to stay competitive.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

The New Cost of Compliance: Investing in HR Tech

The New Cost of Compliance: Investing in HR Tech

Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.

View stocks
GLP-1s Target Liver Disease

GLP-1s Target Liver Disease

The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.

View stocks
Pharma's Digital Prescription

Pharma's Digital Prescription

Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.

View stocks
View All

Frequently Asked Questions

Everything you need to know about the product and billing.